# US 2019/0241625 A1 · Streptococcus suis Vaccines to Protect Against Reproductive, Nursery-Age, and Growing Pig Diseases and Methods of Making and Use Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0241625 A1
- Document ID: US20190241625A1
- Status: Published application
- Kind: A1
- Application number: 16/118,857
- Filed: 2018-08-31
- Published: 2019-08-08
- Earliest claimed: 2017-08-31
- Assignees: Merial Limited
- Applicants: Merial Inc.
- Inventors: Paulraj Lawrence
- Web page: https://patentgrep.com/patent/US20190241625A1

## CPC

- C07K 14/315: from Streptococcus (G), e.g. Enterococci
- A61K 39/092: {Streptococcus}
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 2039/552: {Veterinary vaccine}
- C12Q 1/6869: Methods for sequencing
- C40B 40/08: Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
- G16B 30/00: ICT specially adapted for sequence analysis involving nucleotides or amino acids
- G16B 50/00: ICT programming tools or database systems specially adapted for bioinformatics
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C40B: COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES (in silico combinatorial libraries of nucleic acids, proteins or peptides G16B35/00; in silico combinatorial chemistry G16C20/60)
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY

## Abstract

The present invention provides S. suis strains that elicit an immune response in animal S. suis, compositions comprising said strains, methods of vaccination against S. suis, and kits for use with such methods and compositions. The invention further provides a comprehensive, unambiguous method of capsular typing based on whole genome sequencing and bioinformatics. This capsular typing approach can accurately identify serotypes even when strains possess novel capsular loci and can be used to determine which strains to include when formulating vaccines, including herd specific vaccines.

## Claims

### Claim 1

A vaccine or immunogenic composition comprising a S. suis purified polynucleotide that elicits an immunogenic response in an animal, wherein the polynucleotide comprises:
a) an amino acid sequence having at least 80% sequence identity to a polynucleotide having the sequence as set forth in SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, or 31; or
b) a conservative variant of the polypeptide having the sequence as set forth in SEQ ID NO:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 or 32.

### Claim 2 (depends on 1)

The vaccine or immunogenic composition of claim 1 capable of providing a safe and effective immune response in porcine against reproductive, nursery-age, and growing pig diseases caused by S. suis.

### Claim 3 (depends on 2)

The vaccine or immunogenic composition of claim 2 having a polynucleotide encoding a conservative variant of the polypeptide of the sequence as set forth in SEQ ID NOs: 4, 8, 12, or combinations thereof.

### Claim 4 (depends on 3)

The vaccine or immunogenic composition of claim 3 further comprising a pharmaceutically or veterinary acceptable vehicle, diluent or excipient.

### Claim 5 (depends on 4)

The vaccine or immunogenic composition of claim 4 further comprising an adjuvant.

### Claim 6 (depends on 2)

The vaccine or immunogenic composition of claim 2 which provides a protective immune response in porcine against virulent S. suis challenge.

### Claim 7 (depends on 2)

A method of vaccinating a porcine animal comprising at least one administration of the vaccine or immunogenic composition of any one of claim 2.

### Claim 8 (depends on 7)

The method of claim 7 wherein the porcine is a sow from about 3 weeks to about 6 weeks prefarrowing.

### Claim 9 (depends on 8)

The method of claim 8 wherein the resulting sows have reduced reproductive, nursery-age, and growing pig diseases as compared to unvaccinated sows.

### Claim 10 (depends on 2)

A method of preventing or treating reproductive, nursery-age, or growing pig diseases in a swine comprising administering to the swine the vaccine of claim 2.

### Claim 11

A method of capsule typing of S. suis comprising:
isolating samples from an infected animal;
extracting genomic DNA;
purifying genomic DNA;
preparing libraries for sequencing the genomic DNA;
sequencing the genomic DNA;
de novo assembling a draft genome; and
deriving the capsule type from the draft genome by mapping selected gene references to a genomic database.

### Claim 12 (depends on 11)

The method of claim 11 wherein the capsule type is used to formulate vaccines to match field strains.

### Claim 13 (depends on 12)

The method of claim 12 wherein the field strains are selected from the group of SEQ ID NOS: 33-67.

### Claim 14 (depends on 12)

The method of claim 12 which provides improved protection against S. suis infection compared to other vaccine formulation methods.

### Claim 15

A kit for eliciting or inducing an immunological or protective response against S. suis in an animal comprising:
an S. suis immunological composition; and
instructions for performing the method of delivery in an effective amount for eliciting an immune response in the animal.

### Claim 16 (depends on 15)

The kit of claim 15 wherein the immunological composition comprises:
a) an amino acid sequence having at least 80% sequence identity to a polynucleotide having the sequence as set forth in SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, or 31; or
b) a conservative variant of the polypeptide having the sequence as set forth in SEQ ID NO:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 or 32; or
c) a combination thereof.

### Claim 17 (depends on 16)

The kit of claim 16 wherein the immunological composition is a polynucleotide encoding a conservative variant of the polypeptide selected from the group consisting of SEQ ID NOs: 4, 8, 12, or combinations thereof.

### Claim 18 (depends on 11)

A kit for identifying strains of S. suis comprising materials and reagents for collecting samples and materials and reagents for performing the method of capsule typing of claim 11.

### Claim 19 (depends on 2)

A kit for prime-boost vaccination comprising at least two vials: a first vial containing a vaccine or immunogenic composition of claim 2 for the prime-vaccination, and a second vial containing a different vaccine or immunogenic composition of claim 2 for the boost-vaccination.

### Claim 20 (depends on 19)

The kit according to claim 19 further comprising additional first or second vials for additional prime-vaccinations or additional boost-vaccinations.
